A few anti-integrin monoclonal antibodies are on the market as drugs, such as natalizumab, an anti-α4β1 integrin for multiple sclerosis [108], abciximab and efalizumab [109], an anti-αIIbβ3a integrin for thrombosis and an anti-αLβ2 for psoriasis while others are in clinical development. This evidence concerns the gene AFM and psoriasis.